Literature DB >> 16940866

Diagnosis and treatment of new world hantavirus infections.

Gregory J Mertz1, Brian Hjelle, Mark Crowley, Gary Iwamoto, Vinko Tomicic, Pablo A Vial.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to summarize the current knowledge regarding the diagnosis and treatment of indigenous new world hantavirus infections. RECENT
FINDINGS: Recent studies have defined the incubation period of new world hantavirus infections, provided additional evidence for person-to-person transmission of Andes virus, described a rapid method for the presumptive diagnosis of infection in the cardiopulmonary phase through a review of the peripheral smear, and suggested that intravenous ribavirin is probably not effective for the treatment of new world hantavirus infections when started in the cardiopulmonary phase.
SUMMARY: Presumptive diagnosis may be made by a review of the peripheral blood smear after the onset of the cardiopulmonary phase. Critical care management includes the avoidance of fluid overload, pressors to maintain cardiac output, and the use of extracorporeal membrane oxygenation in the most severe cases, but treatment with intravenous ribavirin is probably not effective.

Entities:  

Mesh:

Year:  2006        PMID: 16940866     DOI: 10.1097/01.qco.0000244048.38758.1f

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  36 in total

1.  Truncated hantavirus nucleocapsid proteins for serotyping Sin Nombre, Andes, and Laguna Negra hantavirus infections in humans and rodents.

Authors:  Takaaki Koma; Kumiko Yoshimatsu; Noemi Pini; David Safronetz; Midori Taruishi; Silvana Levis; Rika Endo; Kenta Shimizu; Shumpei P Yasuda; Hideki Ebihara; Heinz Feldmann; Delia Enria; Jiro Arikawa
Journal:  J Clin Microbiol       Date:  2010-03-24       Impact factor: 5.948

Review 2.  Treatment of hantavirus pulmonary syndrome.

Authors:  Colleen B Jonsson; Jay Hooper; Gregory Mertz
Journal:  Antiviral Res       Date:  2007-11-21       Impact factor: 5.970

3.  Central nervous system complications following Hanta virus cardiopulmonary syndrome.

Authors:  Branko N Huisa; John E Chapin; John C Adair
Journal:  J Neurovirol       Date:  2009-04       Impact factor: 2.643

4.  The Hantavirus Glycoprotein G1 Tail Contains Dual CCHC-type Classical Zinc Fingers.

Authors:  D Fernando Estrada; Daniel M Boudreaux; Dalian Zhong; Stephen C St Jeor; Roberto N De Guzman
Journal:  J Biol Chem       Date:  2009-01-29       Impact factor: 5.157

5.  Extracorporeal membrane oxygenation for the treatment of severe refractory hantavirus cardiopulmonary syndrome.

Authors:  Han Yao; Emily G McDonald
Journal:  CMAJ       Date:  2016-11-28       Impact factor: 8.262

6.  Pathophysiology of hantavirus pulmonary syndrome in rhesus macaques.

Authors:  David Safronetz; Joseph Prescott; Friederike Feldmann; Elaine Haddock; Rebecca Rosenke; Atsushi Okumura; Douglas Brining; Eric Dahlstrom; Stephen F Porcella; Hideki Ebihara; Dana P Scott; Brian Hjelle; Heinz Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

7.  Andes virus antigens are shed in urine of patients with acute hantavirus cardiopulmonary syndrome.

Authors:  Paula Godoy; Delphine Marsac; Elias Stefas; Pablo Ferrer; Nicole D Tischler; Karla Pino; Pablo Ramdohr; Pablo Vial; Pablo D T Valenzuela; Marcela Ferrés; Francisco Veas; Marcelo López-Lastra
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

Review 8.  Hantaviruses as zoonotic pathogens in Germany.

Authors:  Detlev H Krüger; Rainer G Ulrich; Jörg Hofmann
Journal:  Dtsch Arztebl Int       Date:  2013-07-08       Impact factor: 5.594

9.  Hantavirus pulmonary syndrome in Canada: An overview of clinical features, diagnostics, epidemiology and prevention.

Authors:  M A Drebot; S Jones; A Grolla; D Safronetz; J E Strong; G Kobinger; R L Lindsay
Journal:  Can Commun Dis Rep       Date:  2015-06-04

10.  The adaptive immune response does not influence hantavirus disease or persistence in the Syrian hamster.

Authors:  Joseph Prescott; David Safronetz; Elaine Haddock; Shelly Robertson; Dana Scott; Heinz Feldmann
Journal:  Immunology       Date:  2013-10       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.